Last Price
0.372
Today's Change
-0.02 (5.10%)
Day's Change
0.365 - 0.396
Trading Volume
480,102
Exchange: NASDAQ Capital Market NASDAQ Capital Market
Currency: USD USD
Sector: Healthcare - Healthcare Healthcare - Healthcare
CEO: Dr. John Edwin Friend II, M.D. Dr. John Edwin Friend II, M.D.
Full Time Employees: 9 9
IPO Date: 1999-01-06 1999-01-06
CIK: 0001075880 0001075880
ISIN: US48669G1058 US48669G1058
CUSIP: 48669G105 48669G105
Beta: 2.10 2.10
Last Dividend: 0.00 0.00
Dcf Diff: 0.25 0.25
Dcf: 0.12 0.12
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.